Ryzodeg® (insulin degludec and insulin aspart) (NN5401)

:Type 1 and 2 diabetes
:Filed for registration

A soluble coformulation of the basal analogue insulin degludec (Tresiba®) and insulin aspart (NovoRapid®, or NovoLog® in the US), a rapid-acting mealtime insulin, that reduces the risk of hypoglycaemia compared with premix insulin. Approved in the Europe, Japan and other markets. Additional data required by the US FDA are being generated for the planned resubmission.


Company announcements
Increased operating profit by 18% in the first quarter of 2013 (01 May 2013)
Novo Nordisk receives Complete Response Letter in the US for Tresiba® and Ryzodeg® (10 Feb 2013)
Novo Nordisk increased operating profit by 32% in 2012 (31 Jan 2013)
Read more company announcements

Press releases
Ryzodeg® provides successful glycaemic control with fewer injections than a basal-bolus regimen (18 Sep 2014)
Mexico first country to launch Ryzodeg® (01 Sep 2014)
Novo Nordisk accepts fine for violating disclosure obligation in Denmark (18 Aug 2014)
Read more press releases

Scientific abstracts

No scientific abstracts matching the search criteria

You can search for more clinical trials on http://clinicaltrials.gov